PODD
Insulet Corporation

1,874
Mkt Cap
$22.77B
Volume
411,681.00
52W High
$353.50
52W Low
$226.50
PE Ratio
98.44
PODD Fundamentals
Price
$323.46
Prev Close
$329.22
Open
$327.90
50D MA
$327.13
Beta
0.88
Avg. Volume
657,215.90
EPS (Annual)
$5.78
P/B
15.56
Rev/Employee
$531,179.49
Loading...
Loading...
News
all
press releases
Insulet Announces Appointment of Robert L. Huffines to its Board of Directors
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the appointment of Robert...
Business Wire·23h ago
News Placeholder
More News
News Placeholder
ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines
Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.
Zacks·2d ago
News Placeholder
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Zacks·2d ago
News Placeholder
Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs
TMO delivers robust Q3 results, fueled by margin growth, new launches and AI-focused strategic initiatives.
Zacks·2d ago
News Placeholder
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Zacks·3d ago
News Placeholder
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
Zacks·9d ago
News Placeholder
R&D spending now can have big payoffs later for companies
Just how long have people been saying you have to spend money to make money"?Historians maintain that this particular proverb goes all that way back to the Roman playwright Titus Maccius Plautus, who...
TheStreet.com·10d ago
News Placeholder
Neogen Q1 Earnings Miss Estimates, Revenues Beat, Stock Climbs
NEOG's Q1 earnings decline 42.9% year over year, while revenues of $209.2 million top the consensus mark.
Zacks·14d ago
News Placeholder
Insulet to Host Investor Day on November 20, 2025
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, will host an Investor Day at the Companys Acton...
Business Wire·14d ago
News Placeholder
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Zacks·17d ago

Latest PODD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.